[HTML][HTML] Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA

Y Wang, X Meng, A Wang, X Xie, Y Pan… - … England Journal of …, 2021 - Mass Medical Soc
… We determined that a total of 6396 carriers of CYP2C19 loss-of-function alleles would … in
new stroke (primary outcome) in the ticagrelor–aspirin group as compared with the clopidogrel–…

[HTML][HTML] Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA

Y Yang, W Chen, Y Pan, H Yan, X Meng, L Liu… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
… Proportion of HOPR stratified by dual antiplatelet therapy and CYP2C19 loss-of-function
carrier status at 90±7 days. HOPR indicates high on-treatment platelet reactivity; ADP, …

Ticagrelor Aspirin vs Clopidogrel Aspirin in CYP2C19 Loss-of-Function Carriers With Minor Stroke or TIA Stratified by Risk Profile

A Wang, X Meng, X Tian, Y Zuo, PM Bath, H Li, X Xie… - Neurology, 2023 - AAN Enterprises
… (LOF) alleles according to the risk of recurrent stroke may be … of ticagrelor aspirin with
clopidogrel aspirin in CYP2C19 LOF carriers with minor stroke or transient ischemic attack (TIA) …

One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA Trial

X Meng, A Wang, X Tian, C Johnston, H Li, PM Bath… - Neurology, 2024 - AAN Enterprises
… patients with minor stroke or TIA with TIACYP2C19 loss-of-function, ticagrelor plus aspirin
for 21 days is superior to clopidogrel plus aspirin in reducing the 1-year risk of recurrent stroke. …

Ticagrelor-Aspirin versus Clopidogrel-Aspirin in CYP2C19 Loss-of-Function Carriers with Minor Stroke or TIA Stratified by Risk Profile

A Wang, X Meng, X Tian, Y Zuo, PM Bath… - … - nottingham-repository.worktribe.com
… –aspirin than clopidogrel–aspirin. Classification of Evidence: This study provides … CYP2C19
30 LOF carriers with minor stroke or TIA at low risk, but not at high risk, of recurrent 31 stroke

Ticagrelor-Aspirin versus Clopidogrel-Aspirin among CYP2C19 Loss-of-Function Carriers with Minor Stroke or TIA in Relation to Renal Function: A Post Hoc Analysis …

A Wang, Y Wang, X Xie, X Tian… - Annals of Internal … - nottingham-repository.worktribe.com
CYP2C19 LOF carriers 346 with minor stroke or TIA, ticagrelor-aspirin compared with
clopidogrel-aspirin was 347 associated with a reduced risk of recurrent stroke and without any …

Ticagrelor Versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA (CHANCE-2) Trial: One-Year Outcomes

X Meng, A Wang, X Tian, SC Johnston, H Li, P Bath… - papers.ssrn.com
stroke or TIA who carried CYP2C19 loss-of-functionticagrelor (180 mg on day 1 followed
by 90 mg twice daily on days 2 through 90) and placebo clopidogrel or to receive clopidogrel (…

… and risk with ticagrelor and aspirin in individuals with acute ischemic stroke or transient ischemic attack who carry CYP2C19 loss-of-function alleles: a secondary …

Y Pan, X Meng, A Jin, SC Johnston, H Li… - JAMA …, 2022 - jamanetwork.com
… patients with minor ischemic stroke or TIA who carried CYP2C19 LOF alleles, we found that
the benefit with ticagrelor and aspirin compared with clopidogrel and aspirin predominately …

… of genotype-guided antiplatelet therapy in Asian ischemic stroke patients: ticagrelor as an alternative to clopidogrel in patients with CYP2C19 loss of function …

K Narasimhalu, YK Ang, DSY Tan, DA De Silva… - Clinical drug …, 2020 - Springer
… The prevalence of LOF allele carriers was previously reported in 506 genomic samples of …
a recurrent ischemic stroke among carriers and non-carriers taking clopidogrel from a Chinese …

… of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified …

X Xie, SC Johnston, A Wang, Q Xu, PM Bath… - JAMA Network …, 2023 - jamanetwork.com
… -aspirin combination among carriers of CYP2C19 loss-of-function (LOF) … with TIA or minor
ischemic stroke with ticagrelor-aspirin or clopidogrel-aspirin based on background CYP2C19